Study | N-3 PUFA Dose (g/d) | % Change in serum TG levels | Duration (wks) | Additional Dietary Modifications | Study | N-3 PUFA Dose (g/d) | % Change in serum TG levels | Duration (wks) | Additional Dietary Modifications |
---|---|---|---|---|---|---|---|---|---|
Normolipidemic Subjects – Modified EPA and/or DHA Intake | Moderately Hyperlipidemic Subjects – Modified EPA and/or DHA Intake | ||||||||
Lara [31] | 5.4 | −15* | 4 | Salmon Based | Ambring [33] |  |  |  |  |
4 | −26* | 8 |  | Group A | 4.1 | −9* | 4 | Mediterranean Based | |
Hallund [32] | Â | Â | Â | Â | Group B | 2.3 | 9 | 4 | Swedish Based |
 Group A | 3.4 | −14 | 8 | Trout Based | Sofi [42] |  |  |  |  |
 Group B | 0.8 | −6 | 8 | Trout Based | Group A | 2.3 | −2 | 10 | High LA diet |
Navas-Carretero [34] | 2.8 | −3.1 | 8 | Oily Fish Based | Group B | 2.3 | −2 | 10 | Moderate LA diet |
Minihane [41] |  |  |  |  | Group C | 2.3 | −12 | 10 | Moderate LA diet |
 Group A | 2 | 3 | 6 | Moderate LA diet | Group D | 2.3 | −2 | 10 | High LA diet |
 Group B | 2 | −5 | 6 | High LA diet | Hamazaki [37] | 0.86 | −17* | 12 |  |
Garcia-Alonso [36] | 0.5 | 0 | 2 | Â | Â | Â | Â | Â | Â |
Baro [35] | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Group A | 0.33 | 2 | 8 |  |  |  |  |  |  |
 Group B | 0.33 | 1 | 4 |  |  |  |  |  |  |
Coates [38] | 0.185 | −27* | 12 |  |  |  |  |  |  |
Normolipidemic Subjects – Modified ALA Intake | Moderately Hyperlipidemic Subjects – Modified ALA Intake | ||||||||
Stuglin [39] | 6.98 | 41* | 4 | Ground Flaxseed | 8.53 | 3 | 52 | Ground Flaxseed | |
Patenaude [40] | Â | Â | Â | Â | Â | Â | Â | Â | |
 Group A | 6.5 | −11 | 4 | Ground Flaxseed |  |  |  |  |  |
 Group B | 6.5 | 13 | 4 | Ground Flaxseed |  |  |  |  |  |
 Group C | 5.74 | −20 | 4 | Flaxseed Oil |  |  |  |  |  |
 Group D | 5.74 | 4 | 4 | Flaxseed Oil |  |  |  |  |  |